Literature DB >> 28261899

Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod.

Sidharth Tandon1, Jasmeet Singh1, Surabhi Sinha1, Dr Preeti Sharma2.   

Abstract

Herpes Simplex Virus type 2 is the primary cause of genital ulceration worldwide. The presence of atypical features like deep ulcerations, hypertrophic, or pseudotumoural lesions or unusual location can be a marker for co-infection with HIV. These immunocompromised patients are usually resistant to the conventional antiviral treatment. We present a case of an HIV-infected patient with hypertrophic herpes genitalis, refractory to conventional oral antiviral therapy, who was successfully treated with a combination of oral valcyclovir and topical application of 5% imiquimod.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  HIV; herpes; hypertrophic; imiquimod; topical

Mesh:

Substances:

Year:  2017        PMID: 28261899     DOI: 10.1111/dth.12479

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  3 in total

1.  Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells.

Authors:  Rogelio Valdez; Gabriella Fenkart; Germán G Gornalusse; Lucia Vojtech; Lamar M Fleming; Urvashi Pandey; Sean M Hughes; Claire N Levy; Erin J Dela Cruz; Fernanda L Calienes; Anna C Kirby; Michael F Fialkow; Gretchen M Lentz; Jessica Wagoner; Lichen Jing; David M Koelle; Stephen J Polyak; David N Fredricks; M Juliana McElrath; Anna Wald; Florian Hladik
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

2.  Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge.

Authors:  Jun Hu; John C Krauss; Micheline Moyal-Barracco; Laraine L Washer; Hope K Haefner; Ebony Parker-Featherstone
Journal:  Int J Womens Dermatol       Date:  2021-06-20

3.  Acyclovir-resistant chronic mucocutaneous herpes with good response to the association with imiquimod in an AIDS patient: case report.

Authors:  Suellen Ramos de Oliveira; Ariane Sponchiado Assoni; Thiago Jeunon de Sousa Vargas; Egon Daxbacher
Journal:  An Bras Dermatol       Date:  2022-01-14       Impact factor: 2.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.